= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Bendt

MSACL 2018 EU Abstract

Topic: Small Molecules

Podium Presentation in the Ether on Wednesday at 9:40 (Chair: Grace van der Gugten)

The Singapore Lipidomics Incubator: A Model for Engagement and Translation

Anne Bendt (Presenter)
National University of Singapore

Presenter Bio(s): MSc (Biol), U Greifswald/ Germany
PhD (Biochem), U Cologne/ Germany
PostDoc (mycobacterial lipidomics), U Singapore
Scientific Program Manager; since 2008
Associate Director of the Singapore Lipidomics Incubator; since 2015
Principal Investigator at the Life Sciences Institute/Singapore; since 2015

I am a Principal Investigator in the Singapore Lipidomics Incubator (SLING), anchored within the Life Sciences Institute of the National University of Singapore. In addition to my active research & translation role, I have also been serving as SLING’s Associate Director since 2015.
My main research interests include Lipidomics tools and their applications, especially for development of biomarkers and diagnostics; Infectious Diseases; Translation & Commercialization; Operations.
More info: https://www.lsi.nus.edu.sg/corp/research-programmes/sling/principal-investigators/anne-k-bendt/

Authors: Anne K Bendt (1), Tze Ping Loh (2) and Markus R Wenk (1,3)
(1) Singapore Lipidomics Incubator (SLING) at the Life Sciences Institute, National University of Singapore; (2) Department of Laboratory Medicine, National University Hospital, Singapore; (3) Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore

Abstract

We developed a model of engagement to clinically translate LC-MS/MS-based analytical protocols to measure metabolites (lipids, small molecules) in human plasma. By close interactions with data scientists, clinicians and laboratory medicine, we are translating some of our lab-based technology into assays suitable for clinical applications. A special focus lies in understanding natural variation and population reference values. Data from ongoing studies in multi-ethnic cohorts will be discussed.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no